282 related articles for article (PubMed ID: 25947358)
1. Alternative Treatments For Melanoma: Targeting BCL-2 Family Members to De-Bulk and Kill Cancer Stem Cells.
Mukherjee N; Schwan JV; Fujita M; Norris DA; Shellman YG
J Invest Dermatol; 2015 Sep; 135(9):2155-2161. PubMed ID: 25947358
[TBL] [Abstract][Full Text] [Related]
2. Systemic treatment for BRAF-mutant melanoma: where do we go next?
Menzies AM; Long GV
Lancet Oncol; 2014 Aug; 15(9):e371-81. PubMed ID: 25079100
[TBL] [Abstract][Full Text] [Related]
3. Strides in melanoma announced: maximizing value comes next.
Tuma RS
J Natl Cancer Inst; 2011 Jul; 103(13):997-9. PubMed ID: 21693727
[No Abstract] [Full Text] [Related]
4. Targeted therapy resistance mechanisms and therapeutic implications in melanoma.
Chen G; Davies MA
Hematol Oncol Clin North Am; 2014 Jun; 28(3):523-36. PubMed ID: 24880945
[TBL] [Abstract][Full Text] [Related]
5. The "ART" of Epigenetics in Melanoma: From histone "Alterations, to Resistance and Therapies".
Strub T; Ballotti R; Bertolotto C
Theranostics; 2020; 10(4):1777-1797. PubMed ID: 32042336
[TBL] [Abstract][Full Text] [Related]
6. Melanoma stem cells.
Roesch A
J Dtsch Dermatol Ges; 2015 Feb; 13(2):118-24. PubMed ID: 25631128
[TBL] [Abstract][Full Text] [Related]
7. Novel Therapies for Metastatic Melanoma: An Update on Their Use in Older Patients.
Rogiers A; van den Oord JJ; Garmyn M; Stas M; Kenis C; Wildiers H; Marine JC; Wolter P
Drugs Aging; 2015 Oct; 32(10):821-34. PubMed ID: 26442859
[TBL] [Abstract][Full Text] [Related]
8. Dacarbazine with or without oblimersen (a Bcl-2 antisense oligonucleotide) in chemotherapy-naive patients with advanced melanoma and low-normal serum lactate dehydrogenase: 'The AGENDA trial'.
Bedikian AY; Garbe C; Conry R; Lebbe C; Grob JJ;
Melanoma Res; 2014 Jun; 24(3):237-43. PubMed ID: 24667300
[TBL] [Abstract][Full Text] [Related]
9. Tumor mutational burden and response to programmed cell death protein 1 inhibitors in a case series of patients with metastatic desmoplastic melanoma.
Boussemart L; Johnson A; Schrock AB; Pal SK; Frampton GM; Fabrizio D; Chalmers Z; Lotem M; Gibney G; Russell J; Chmielowski B; Ross JS; Stephens PJ; Miller VA; Ali SM
J Am Acad Dermatol; 2019 Jun; 80(6):1780-1782. PubMed ID: 30576761
[No Abstract] [Full Text] [Related]
10. Melanoma never says die.
Haass NK; Schumacher U
Exp Dermatol; 2014 Jul; 23(7):471-2. PubMed ID: 24684560
[TBL] [Abstract][Full Text] [Related]
11. Apoptosis and melanoma chemoresistance.
Soengas MS; Lowe SW
Oncogene; 2003 May; 22(20):3138-51. PubMed ID: 12789290
[TBL] [Abstract][Full Text] [Related]
12. Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K-AKT-mTOR Pathway Inhibitors.
Kong Y; Si L; Li Y; Wu X; Xu X; Dai J; Tang H; Ma M; Chi Z; Sheng X; Cui C; Guo J
Clin Cancer Res; 2016 Feb; 22(4):1018-27. PubMed ID: 26490311
[TBL] [Abstract][Full Text] [Related]
13. bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice.
Jansen B; Schlagbauer-Wadl H; Brown BD; Bryan RN; van Elsas A; Müller M; Wolff K; Eichler HG; Pehamberger H
Nat Med; 1998 Feb; 4(2):232-4. PubMed ID: 9461199
[TBL] [Abstract][Full Text] [Related]
14. Is there a role for targeting vascular endothelial growth factor/receptor axis in the treatment of patients with metastatic melanoma?
Kim KB
Cancer; 2013 Feb; 119(3):477-80. PubMed ID: 22915026
[No Abstract] [Full Text] [Related]
15. [New treatment options for metastatic melanoma].
Tietze JK; Berking C
Dtsch Med Wochenschr; 2014 Jul; 139(28-29):1462-7. PubMed ID: 24983194
[No Abstract] [Full Text] [Related]
16. Improving patient outcomes to targeted therapies in melanoma.
Eroglu Z; Smalley KS; Sondak VK
Expert Rev Anticancer Ther; 2016 Jun; 16(6):633-41. PubMed ID: 27137746
[TBL] [Abstract][Full Text] [Related]
17. Melanoma: understanding relevant molecular pathways as well as available and emerging therapies.
McKibbin T
Am J Manag Care; 2015 Sep; 21(10 Suppl):S224-33. PubMed ID: 26619296
[TBL] [Abstract][Full Text] [Related]
18. [Prognostic and predictive markers of malignant melanoma].
Rásó E; Barbai T; Gyõrffy B; Tímár J
Magy Onkol; 2013 Jun; 57(2):79-83. PubMed ID: 23795352
[TBL] [Abstract][Full Text] [Related]
19. [Targeted molecular therapies (except immunotherapy)].
Roux J; Pages C; Lebbé C
Bull Cancer; 2014 Dec; 101 Suppl 2():S25-36. PubMed ID: 25776764
[TBL] [Abstract][Full Text] [Related]
20. HLA-A*26 Is Correlated With Response to Nivolumab in Japanese Melanoma Patients.
Ishida Y; Otsuka A; Tanaka H; Levesque MP; Dummer R; Kabashima K
J Invest Dermatol; 2017 Nov; 137(11):2443-2444. PubMed ID: 28736235
[No Abstract] [Full Text] [Related]
[Next] [New Search]
